Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The study “The Potential Impact of CAR T-Cell Treatment Delays on Society,” which was published in the August issue of AJMC®, was the focus of an article from Hematology Advisor. The study concluded that the social value of chimeric antigen receptor (CAR) T-cell therapy is significantly limited by treatment delays and that efficient payment mechanisms, adequate capital, and payment policy reform are urgently needed to increase patient access and maximize the value of the treatment.
Mountain Grove News Journal’s article on the impact of depression referred to a 2014 study published in AJMC®, which examined health claims data to assess medication adherence rates and healthcare costs for psychiatric patients. The study, “Pharmacogenetic-Guided Psychiatric Intervention Associated With Increased Adherence and Cost Savings,” found that patients whose clinicians had access to pharmacogenetic test results had increased adherence and overall cost savings.
AJMC®’s video series “Identifying Secondary Progressive Multiple Sclerosis” was highlighted by Multiple Sclerosis News Today. The video series, which features multiple key opinion leaders, includes discussions on the nature and cost of Multiple Sclerosis, debates on whether it is truly an autoimmune disease, and more.
Both EcoWatch and Xherald included an article from AJMC.com, the website of AJMC®, in their pieces on the impact of sugary drinks. The article, “Large European Study Links Soda Consumption to Greater Risk of Mortality, Including From Parkinson,” reported on study findings showing that soft drinks were linked to a greater risk of death, as well as a higher chance of dying from Parkinson disease.
The National Pharmaceutical Council included AJMC®’s interview with Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, in its Wednesday newsfeed. During the interview, Chari discussed the importance of real-world evidence in multiple myeloma.